| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Hypertrophic | 157 | 2026 | 796 | 27.760 |
Why?
|
| Atrial Fibrillation | 25 | 2026 | 871 | 5.790 |
Why?
|
| Ventricular Outflow Obstruction | 19 | 2025 | 118 | 5.560 |
Why?
|
| Death, Sudden, Cardiac | 52 | 2026 | 366 | 5.430 |
Why?
|
| Defibrillators, Implantable | 30 | 2024 | 273 | 4.890 |
Why?
|
| Magnetic Resonance Imaging, Cine | 23 | 2026 | 116 | 4.380 |
Why?
|
| Heart Failure | 29 | 2026 | 949 | 4.080 |
Why?
|
| Tachycardia, Ventricular | 11 | 2024 | 131 | 3.080 |
Why?
|
| Anti-Arrhythmia Agents | 8 | 2026 | 102 | 2.540 |
Why?
|
| Ventricular Septum | 8 | 2022 | 30 | 2.490 |
Why?
|
| Myocardium | 15 | 2026 | 301 | 2.260 |
Why?
|
| Humans | 181 | 2026 | 64882 | 2.220 |
Why?
|
| Contrast Media | 17 | 2026 | 430 | 2.190 |
Why?
|
| Cardiac Surgical Procedures | 15 | 2023 | 268 | 1.980 |
Why?
|
| Risk Assessment | 22 | 2025 | 2093 | 1.930 |
Why?
|
| Middle Aged | 76 | 2026 | 18184 | 1.910 |
Why?
|
| Heart Transplantation | 10 | 2024 | 180 | 1.860 |
Why?
|
| Gadolinium | 12 | 2024 | 110 | 1.860 |
Why?
|
| Electrocardiography | 12 | 2024 | 553 | 1.780 |
Why?
|
| Male | 90 | 2026 | 30916 | 1.730 |
Why?
|
| Catheter Ablation | 4 | 2026 | 156 | 1.680 |
Why?
|
| Heart Septum | 10 | 2022 | 57 | 1.660 |
Why?
|
| Exercise Test | 5 | 2026 | 256 | 1.630 |
Why?
|
| Risk Factors | 42 | 2026 | 5400 | 1.620 |
Why?
|
| Heart Aneurysm | 6 | 2021 | 23 | 1.570 |
Why?
|
| Adult | 67 | 2026 | 17286 | 1.550 |
Why?
|
| Treatment Outcome | 31 | 2026 | 5773 | 1.490 |
Why?
|
| Female | 78 | 2026 | 33885 | 1.460 |
Why?
|
| Ablation Techniques | 5 | 2020 | 26 | 1.450 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2021 | 168 | 1.440 |
Why?
|
| Echocardiography | 14 | 2026 | 510 | 1.420 |
Why?
|
| Amyloidosis | 3 | 2022 | 68 | 1.410 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 136 | 1.410 |
Why?
|
| Retrospective Studies | 33 | 2026 | 6830 | 1.390 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2023 | 2237 | 1.360 |
Why?
|
| Ventricular Fibrillation | 8 | 2023 | 107 | 1.350 |
Why?
|
| Aged | 45 | 2026 | 14899 | 1.340 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 5 | 2023 | 28 | 1.200 |
Why?
|
| Follow-Up Studies | 17 | 2025 | 2481 | 1.180 |
Why?
|
| Electric Countershock | 8 | 2024 | 105 | 1.130 |
Why?
|
| Heart Ventricles | 10 | 2022 | 266 | 1.080 |
Why?
|
| Ventricular Function, Left | 14 | 2026 | 278 | 1.070 |
Why?
|
| Primary Prevention | 4 | 2021 | 136 | 1.060 |
Why?
|
| Disopyramide | 2 | 2025 | 11 | 1.050 |
Why?
|
| Young Adult | 29 | 2025 | 4787 | 1.050 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2024 | 45 | 0.970 |
Why?
|
| Vascular Diseases | 2 | 2024 | 81 | 0.960 |
Why?
|
| Heart Atria | 2 | 2026 | 137 | 0.930 |
Why?
|
| Stroke | 4 | 2024 | 1208 | 0.930 |
Why?
|
| Symptom Assessment | 1 | 2026 | 48 | 0.930 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 20 | 0.920 |
Why?
|
| Predictive Value of Tests | 20 | 2026 | 1103 | 0.910 |
Why?
|
| Mitral Valve | 5 | 2023 | 126 | 0.900 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 30 | 0.880 |
Why?
|
| Survival Rate | 11 | 2024 | 843 | 0.870 |
Why?
|
| Athletes | 7 | 2024 | 109 | 0.840 |
Why?
|
| Papillary Muscles | 2 | 2015 | 16 | 0.840 |
Why?
|
| Precision Medicine | 2 | 2022 | 128 | 0.830 |
Why?
|
| Quality of Life | 7 | 2024 | 1255 | 0.820 |
Why?
|
| Stroke Volume | 10 | 2026 | 342 | 0.800 |
Why?
|
| Prognosis | 22 | 2026 | 1774 | 0.790 |
Why?
|
| Phenotype | 15 | 2024 | 1231 | 0.780 |
Why?
|
| Atrial Appendage | 1 | 2024 | 41 | 0.780 |
Why?
|
| Cicatrix | 8 | 2026 | 62 | 0.740 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2020 | 20 | 0.740 |
Why?
|
| Cardiovascular System | 1 | 2022 | 40 | 0.720 |
Why?
|
| Return to Sport | 2 | 2021 | 14 | 0.710 |
Why?
|
| Adolescent | 20 | 2025 | 6286 | 0.680 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 106 | 0.670 |
Why?
|
| Disease Progression | 9 | 2026 | 1214 | 0.650 |
Why?
|
| Hemodynamics | 3 | 2017 | 251 | 0.630 |
Why?
|
| Time Factors | 14 | 2026 | 3752 | 0.620 |
Why?
|
| Longevity | 2 | 2017 | 117 | 0.600 |
Why?
|
| Aortic Valve | 2 | 2020 | 181 | 0.600 |
Why?
|
| Cardiotonic Agents | 3 | 2018 | 54 | 0.600 |
Why?
|
| Sports | 4 | 2024 | 98 | 0.600 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2023 | 124 | 0.590 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 62 | 0.590 |
Why?
|
| Exercise Tolerance | 2 | 2025 | 84 | 0.580 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 16 | 0.570 |
Why?
|
| Referral and Consultation | 2 | 2019 | 437 | 0.570 |
Why?
|
| Child | 16 | 2024 | 4602 | 0.560 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 110 | 0.540 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 15 | 0.540 |
Why?
|
| Waiting Lists | 1 | 2018 | 56 | 0.530 |
Why?
|
| Kidney Diseases | 1 | 2019 | 177 | 0.530 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 171 | 0.530 |
Why?
|
| Critical Pathways | 1 | 2017 | 31 | 0.520 |
Why?
|
| Heart | 6 | 2024 | 297 | 0.510 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 190 | 0.510 |
Why?
|
| Guideline Adherence | 1 | 2019 | 302 | 0.510 |
Why?
|
| Cohort Studies | 11 | 2026 | 2609 | 0.500 |
Why?
|
| Obesity | 1 | 2025 | 1264 | 0.500 |
Why?
|
| Systole | 5 | 2021 | 109 | 0.490 |
Why?
|
| Fibrosis | 8 | 2024 | 172 | 0.480 |
Why?
|
| Mutation | 10 | 2024 | 2656 | 0.460 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2022 | 277 | 0.460 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 25 | 0.450 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 158 | 0.450 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 5595 | 0.450 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2026 | 187 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 735 | 0.440 |
Why?
|
| Angina, Stable | 1 | 2014 | 11 | 0.440 |
Why?
|
| Disease Management | 6 | 2020 | 233 | 0.430 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 41 | 0.420 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2022 | 23 | 0.410 |
Why?
|
| Coronary Vessels | 1 | 2014 | 123 | 0.410 |
Why?
|
| Heart Failure, Diastolic | 1 | 2013 | 9 | 0.400 |
Why?
|
| Coronary Angiography | 1 | 2014 | 210 | 0.400 |
Why?
|
| Incidence | 6 | 2022 | 1412 | 0.390 |
Why?
|
| Electrodes | 1 | 2013 | 39 | 0.380 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2014 | 317 | 0.360 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 162 | 0.350 |
Why?
|
| Anticoagulants | 4 | 2024 | 522 | 0.350 |
Why?
|
| Oxygen Consumption | 2 | 2026 | 213 | 0.350 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 463 | 0.340 |
Why?
|
| Benzylamines | 2 | 2022 | 35 | 0.340 |
Why?
|
| United States | 12 | 2026 | 8071 | 0.320 |
Why?
|
| Recovery of Function | 4 | 2019 | 291 | 0.320 |
Why?
|
| Heart Arrest | 2 | 2022 | 175 | 0.320 |
Why?
|
| Global Health | 4 | 2026 | 180 | 0.320 |
Why?
|
| Genotype | 5 | 2026 | 672 | 0.310 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1556 | 0.290 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 99 | 0.290 |
Why?
|
| Risk Management | 1 | 2008 | 36 | 0.280 |
Why?
|
| Demography | 2 | 2026 | 178 | 0.280 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 59 | 0.280 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1414 | 0.280 |
Why?
|
| Massachusetts | 3 | 2020 | 2140 | 0.280 |
Why?
|
| Hospitalization | 2 | 2026 | 1383 | 0.270 |
Why?
|
| Adipose Tissue | 1 | 2010 | 299 | 0.270 |
Why?
|
| Nursing Staff, Hospital | 1 | 2008 | 72 | 0.270 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2019 | 117 | 0.270 |
Why?
|
| Comorbidity | 2 | 2021 | 1112 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1655 | 0.250 |
Why?
|
| Mass Screening | 1 | 2012 | 695 | 0.250 |
Why?
|
| Medical Errors | 1 | 2008 | 198 | 0.250 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 292 | 0.250 |
Why?
|
| Bibliometrics | 1 | 2026 | 35 | 0.240 |
Why?
|
| Coronary Circulation | 1 | 2025 | 55 | 0.230 |
Why?
|
| Cardiology | 2 | 2019 | 169 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2026 | 730 | 0.220 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2025 | 53 | 0.220 |
Why?
|
| Gadolinium DTPA | 4 | 2018 | 84 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 861 | 0.220 |
Why?
|
| Asymptomatic Diseases | 3 | 2026 | 52 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2026 | 881 | 0.210 |
Why?
|
| Age Factors | 5 | 2024 | 1580 | 0.210 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 11 | 0.210 |
Why?
|
| Uracil | 2 | 2022 | 36 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1275 | 0.210 |
Why?
|
| Prospective Studies | 9 | 2025 | 3304 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 736 | 0.210 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2022 | 98 | 0.200 |
Why?
|
| Reproducibility of Results | 7 | 2026 | 1690 | 0.200 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 168 | 0.200 |
Why?
|
| Periodicals as Topic | 1 | 2026 | 178 | 0.200 |
Why?
|
| Death, Sudden | 1 | 2023 | 31 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 189 | 0.200 |
Why?
|
| Patient Selection | 5 | 2018 | 483 | 0.200 |
Why?
|
| Soccer | 1 | 2022 | 13 | 0.190 |
Why?
|
| Prealbumin | 1 | 2022 | 21 | 0.190 |
Why?
|
| Interatrial Block | 1 | 2022 | 2 | 0.190 |
Why?
|
| Boston | 2 | 2020 | 257 | 0.190 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 93 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 988 | 0.180 |
Why?
|
| Consensus | 2 | 2021 | 181 | 0.180 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 17 | 0.180 |
Why?
|
| Echocardiography, Doppler | 3 | 2017 | 133 | 0.180 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 333 | 0.170 |
Why?
|
| Ontario | 1 | 2021 | 45 | 0.170 |
Why?
|
| Writing | 1 | 2021 | 43 | 0.170 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.170 |
Why?
|
| Heart Conduction System | 1 | 2021 | 50 | 0.170 |
Why?
|
| Sarcomeres | 4 | 2022 | 51 | 0.170 |
Why?
|
| Prevalence | 6 | 2023 | 1437 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 159 | 0.170 |
Why?
|
| Image Enhancement | 3 | 2021 | 194 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 98 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2020 | 7 | 0.160 |
Why?
|
| Judgment | 1 | 2020 | 35 | 0.160 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 2 | 2017 | 14 | 0.160 |
Why?
|
| Reference Standards | 1 | 2020 | 76 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 297 | 0.160 |
Why?
|
| Syncope | 1 | 2020 | 41 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 58 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 151 | 0.160 |
Why?
|
| Diseases in Twins | 1 | 2020 | 56 | 0.160 |
Why?
|
| Safety | 1 | 2020 | 143 | 0.150 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 130 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 160 | 0.150 |
Why?
|
| Ethanol | 2 | 2020 | 329 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 152 | 0.150 |
Why?
|
| Genomics | 1 | 2022 | 383 | 0.150 |
Why?
|
| Sex Factors | 2 | 2019 | 991 | 0.150 |
Why?
|
| Patients | 1 | 2020 | 114 | 0.150 |
Why?
|
| Europe | 4 | 2024 | 199 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 120 | 0.140 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2018 | 39 | 0.140 |
Why?
|
| Myocardial Reperfusion | 1 | 2018 | 23 | 0.140 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2017 | 27 | 0.140 |
Why?
|
| Health Status | 2 | 2018 | 447 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 1472 | 0.140 |
Why?
|
| Sotalol | 1 | 2017 | 9 | 0.130 |
Why?
|
| Fabry Disease | 1 | 2017 | 8 | 0.130 |
Why?
|
| Amiodarone | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hypertension | 1 | 2023 | 609 | 0.130 |
Why?
|
| Cardiac Myosins | 1 | 2017 | 25 | 0.130 |
Why?
|
| Myosin Heavy Chains | 1 | 2017 | 48 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 171 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 147 | 0.120 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 110 | 0.120 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 96 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2017 | 576 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 741 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 161 | 0.120 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 80 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 655 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2017 | 718 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 525 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 88 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 473 | 0.110 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mortality | 3 | 2025 | 159 | 0.100 |
Why?
|
| Inflammation | 1 | 2021 | 1186 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 303 | 0.100 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 27 | 0.100 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2013 | 44 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 407 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 400 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 41 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2697 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 918 | 0.090 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 292 | 0.080 |
Why?
|
| Cause of Death | 2 | 2025 | 221 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2024 | 141 | 0.080 |
Why?
|
| Biopsy | 1 | 2010 | 454 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1137 | 0.070 |
Why?
|
| Hospitals, Voluntary | 1 | 2008 | 1 | 0.070 |
Why?
|
| Medical Informatics Applications | 1 | 2008 | 13 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2017 | 24 | 0.060 |
Why?
|
| Pedigree | 2 | 2017 | 193 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2025 | 70 | 0.060 |
Why?
|
| Internet | 1 | 2008 | 466 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2024 | 15 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 906 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 57 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 198 | 0.050 |
Why?
|
| Universities | 1 | 2024 | 168 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 581 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2023 | 130 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2022 | 23 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2024 | 754 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2025 | 1009 | 0.050 |
Why?
|
| Darkness | 1 | 2021 | 20 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2021 | 11 | 0.040 |
Why?
|
| Cell Communication | 1 | 2022 | 133 | 0.040 |
Why?
|
| Endophenotypes | 1 | 2021 | 9 | 0.040 |
Why?
|
| Workload | 1 | 2022 | 130 | 0.040 |
Why?
|
| Multi-Institutional Systems | 1 | 2020 | 5 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 35 | 0.040 |
Why?
|
| Publication Bias | 1 | 2020 | 21 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 148 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 415 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 110 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 34 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 56 | 0.040 |
Why?
|
| Pandemics | 1 | 2025 | 671 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 8 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2020 | 72 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 192 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 34 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 126 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 241 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 361 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 210 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 273 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 128 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 164 | 0.040 |
Why?
|
| New Jersey | 1 | 2018 | 24 | 0.030 |
Why?
|
| alpha-Galactosidase | 1 | 2017 | 8 | 0.030 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 12 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 129 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 78 | 0.030 |
Why?
|
| Ventricular Function | 1 | 2017 | 22 | 0.030 |
Why?
|
| Dyspnea | 1 | 2018 | 120 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 398 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 394 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2017 | 47 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 144 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2017 | 80 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 113 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 213 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 153 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 21276 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 120 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 90 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1990 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 193 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1313 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 393 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 63 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 201 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 331 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 71 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 218 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 361 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 424 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 74 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 142 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 88 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 186 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 602 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 929 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 414 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 405 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 283 | 0.020 |
Why?
|
| Minnesota | 1 | 2012 | 45 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2052 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 414 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3139 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2018 | 837 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 918 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 698 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 11082 | 0.010 |
Why?
|